

The John S. Legacy Fund

GIVING PLAN



Legacy Giving Profile

Benefunder provides you with IMPACT in your giving: a unique opportunity to find, fund, and follow research that supports your charitable interests in an efficient, cost effective, manner. Please provide answers to the questions below, in turn, we will deliver your customized giving proposal.



Donor

Donor Name(s): John S. Legacy

City: San Diego State: California

University Alumni Associations: Georgetown University

Areas of Research Interests

☒ Health and medicine ☐ Technology ☐ Environment ☐ Arts, Education & Humanities

Areas of research interest: Alzheimer's & Lung Cancer Specific research focus: Early Detection

Current Charitable Giving

What is the focus and the problem you would like to solve through your philanthropic giving?

To save and improve lives for these disease areas through early detection.

List the last 3 non-profit organizations you supported:

1. American Lung Association
2. Alzheimer's Association
3.

Anticipated Giving Plan

Plan to make contributions to the Benefunder Charitable Innovation Fund (*circle one*) Over Time or One Time

Planned initial contribution to the Benefunder Charitable Innovation Fund? \$1,000,000

How do you plan on funding your account? Appreciated stock

eg transfer from existing charitable vehicle, appreciated stock, cash, other

Planned annual contributions: \$ 250,000

Distribution Timeline (*circle one*) 1yr 2yrs 3yrs 4yrs 5yrs 6yrs in perpetuity or other:



The John S. Legacy Fund

To aid in the discovery of early detection of Alzheimer's Disease and Lung Cancer in loving memory of Mr. Legacy's Mother and in honor of a dear friend.



A photograph of the Space Shuttle Columbia during its ascent. The shuttle is white with orange and black external tank and boosters. It is launching from the launch pad, with a large plume of white smoke and fire at its base. The launch pad service structure is visible to the left of the shuttle. The sky is blue with scattered white clouds.

Value

A 'plug and play' charitable giving solution

No set up fees, low overhead, and high efficiency giving

Unrivalled access & ability to open doors


Benefunder can provide access to hundreds of researchers at the top 50 universities and research institutions across the country

High impact philanthropy

A new and innovative funding model that increases measurable impact

The John S. Legacy Fund

Process



A portfolio based approach to giving



John S. Legacy
Giving Profile

Initial Donation
\$1,000,000

Planned Distributions
15% Annually

Research Allocation

40% Alzheimer's Disease


- Early Detection
- Device

27% Lung Cancer

- Therapeutics
- Clinical Trials

23% Neurodegenerative Diseases

10% Other Research



Reflecting what matters to you

Fund Management and Distribution Plan

DISTRIBUTION MANAGEMENT

Establish giving parameters

- Minimum gift size
- Distribution schedule
- Number of researchers in fund

MINIMUM ANNUAL DISTRIBUTION - 15%

INVESTMENT STRATEGY

< \$250,000

aggressive moderate conservative income cash



> \$250,000 self directed

Customized portfolio


Institutional money manager



FEES

- Annual asset management fee - 1.5%
- Administrative fee -10% of recommended distribution
- Graduated fees based on fund balance and recommended distribution

A Side by Side Comparison



Research Impact

Based on a \$1M donation

Benefunder	\$900,000 Research Impact researcher matching researcher engagement & updates
Alzheimer's Association	\$100,000 Research Impact
American Lung Association	\$170,000 Research Impact




Researcher Matches

75+


Other Related Matches

Alzheimer's Disease

EARLY DETECTION






DEVICES





Lung Cancer




THERAPEUTICS



CLINICAL TRIALS




Neurodegenerative





UNRAVELING DEFECTS IN MEMBRANE PROTEINS THAT CAUSE DISEASE

CHARLES SANDERS



ACADEMIC POSITION

“ After a decade of pursuing “basic science” membrane biochemistry, the lab is now at a stage that is directly disease relevant. ”

Professor in Biochemistry, Vanderbilt University School of Medicine
Lyle and Lange Chair of Cardiovascular Research, Biochemistry at Vanderbilt

CURRENT RESEARCH

Whether a protein folds correctly and can fulfill its job in the human body can determine whether an individual will be healthy or will suffer from disease. Therefore, it is necessary to understand the difference between healthy proteins and those that are defective due to mutations or other disease-promoting factors.

Dr. Charles Sanders focuses on discovering how defects in a major class of proteins--membrane proteins--result in diseases, specifically Alzheimer's disease, Charcot-Marie-Tooth disease, kidney fibrosis, and heart rhythm disorders.

His lab uses chemical and physical methods to compare and contrast membrane proteins under both healthy and disease conditions. By understanding how defects in specific membrane proteins result in various diseases, knowledge-based strategies to treat these diseases can be developed.

Disease-related human membrane proteins are among the most difficult to study of the 22,000 different human proteins. Dr. Sanders has dedicated over 20 years of research to these proteins. This experience enables him and his team to tackle membrane protein-disease relationships. Their work provides a bridge between fundamental biochemical and biophysical studies of isolated proteins and studies of proteins in their native cellular environment.

CATEGORY

Neurodegenerative Diseases

AWARDS

Fellow of the American Association
for the Advancement of Science

STAGE OF RESEARCH

Translational

Chancellor's Award, Vanderbilt
University

Anatrace Membrane Protein Award
Biophysical Society



REVOLUTIONIZING THE TARGETING OF CANCER CELLS **BRADLEY MESSMER**



ACADEMIC POSITION

Assistant Project Scientist at Hematologic Malignancies Program,
University of California, San Diego, Moores Cancer Center

“ As government financing of basic science research has plunged, private donors have filled the void raising questions about the future of research for the public good. ”

CURRENT RESEARCH

Dr. Messmer and his team at University of California, San Diego are transforming the targeting of cancer cells by inventing, validating, and commercializing novel technologies. They have developed particles larger and more powerful than typical drugs to latch onto cancer cells. Dr. Messmer's academic research work has focused on the application of novel technologies to problems in cancer diagnosis, monitoring, and treatment. He is passionate about bringing several disciplines together in his research including biology, biochemistry, informatics and engineering, in order to find real world solutions to critical problems in oncology.

Recently, Dr. Messmer and his colleagues have developed a novel DNA nanoparticle platform that may have revolutionary applications in cancer therapy, immunotherapy, and vaccine development.

These DeNA^o particles, as they have been named, specifically recognize cancer cells through multiple interactions with cell surface proteins, and offer greater specificity for effective cancer therapy with minimal side effects.

CATEGORY

Therapeutics and Device

STAGE OF RESEARCH

Translational

HONORS

Recipient of NCI's Innovative
Molecular Analysis Technologies Grant

Member of NanoTumor Center, NIH
Funded Center of Cancer
NanoTechnology Excellence at UCSD



DRAWING BLOOD SAMPLES TO EXAMINE CANCER CELLS

LYUDMILA BAZHENOVA



“ Current statistics shows that 85% of patients diagnosed with lung cancer will eventually die, and I live to see an increase in the survival rate of these patients. ”

ACADEMIC POSITION

Associate Clinical Professor in Department of Medicine, Hematology Oncology
University of California, San Diego

CURRENT RESEARCH

It is critical to identify what exact abnormalities are making the cancer cells grow, as cancer cells constantly change under the pressure of treatment. The typical way to study cancer is to conduct a biopsy, or removing the cancer cells from patients with a needle or surgery to examine them, but this kind of biopsy can lead to several complications.

To address this problem, Dr. Bazhenova focuses her research on liquid biopsy and studies cancer by merely collecting a tube of blood. Using the liquid biopsy as opposed to the traditional tissue biopsy, Dr. Bazhenova hopes to see improvements in treatments and, ultimately, in survival. Outside of her lab, she is a clinician who takes care of cancer patients day and night. Current statistics shows that 85% of patients diagnosed with lung cancer will eventually die, and Dr. Bazhenova is determined to stop it.

Liquid biopsy will allow doctors to predict patient responses to chemotherapy as well as the development of tumor resistance. Simple, approachable and cost-effective, the liquid biopsy will develop screening methods for early detection of cancer.

CATEGORY

Diagnostics

STAGE OF RESEARCH

Translational

AWARDS

Head of Lung Tumor Board

Patients' Choice Award



BIOMARKERS FOR ALZHEIMER'S AND PARKINSON'S DISEASES

HOWARD FEDEROFF



ACADEMIC POSITION

Executive Vice President for Health Sciences, Executive Dean School of Medicine,
Professor of Neurology and Neuroscience at Georgetown University

“ In order to stop this epidemic, we must be able to preclinically identify individuals at high risk, and develop an intervention that can help delay -- or ideally, prevent -- the emergence of disease. ”

CURRENT RESEARCH

Dr. Howard Federoff is using biomarkers to administer a preclinical test that will identify at-risk individuals who are likely to develop Alzheimer's and Parkinson's diseases. The only group to have developed preclinical biomarkers for Alzheimer's disease and move them forward to conduct secondary prevention clinical trials, Dr. Federoff and his team hope to find those who are at greater risk of developing these detrimental neurodegenerative diseases and enable discovery of disease modifying therapeutics.

Dr. Federoff and his lab focus on identifying blood based measures, or biomarkers, that can identify preclinical diseases. Safe, affordable, highly accurate and accessible, preclinical biomarkers are the most effective means to enable these vital secondary prevention trials in preclinical subjects. Once discovered and validated, these biomarkers can be used in similar secondary prevention trials in subjects at risk for Parkinson's

Current projects include:

Furthering the preclinical diagnostic to approach 100% accuracy using additional blood measures to predict phenoconversion.

Using the preclinical tests to define at-risk individuals and enroll them into modifying therapeutic trials.

CATEGORY

Early Detection

STAGE OF RESEARCH

Applied

HONORS

President, American Society
Experimental Neurotherapeutics

Recipient Outstanding Alumni Award,
Earlham College

Elected Fellow of American Association
for the Advancement of Science (AAAS)

Committed To You

At Benefunder we believe it's important that we provide donors with opportunities to contribute to research that matters to them. That is why we only select the top researchers throughout the nation who are working on solutions and innovations that are moving our nation forward. With over 600 researchers on our searchable website and over 10,000 in our database, we are confident donors can create a giving portfolio they know will help inspire groundbreaking research, support significant breakthroughs, and change the world.

A word from our researchers

"I joined Benefunder because it offers an escape from the usual routine, whose surest outcome is frustration. By offering direct pairing of donors with causes, Benefunder frees the researcher of administrative burden, and permits the donor to see the faces of the students and faculty innovators, and the results of his or her support. Through Benefunder, I hope to get back to the important work of mentoring and supporting my students, developing new hypotheses, and inventing new technologies to improve human well-being."

- Darren Lipomi, Assistant Professor of NanoEngineering at University of California, San Diego

About Us

Benefunder is bringing more dollars to research by creating a marketplace that can attract new money, lower costs and increase transparency. This fundamental shift in traditional research funding will reduce our nation's innovation deficit, stimulate the economy, and accelerate the rate and frequency of breakthroughs and cures throughout our nation's universities and research institutions.



benefunder

IMPACT

ACCESS

Easily find the researchers that match your interests

EFFICIENCY

Ensure that more funds reach their intended target

ENGAGEMENT

Receive milestone updates from the researchers you support

Maximize your impact, build your legacy



www.benefunder.org



Info@benefunder.org



3580 Carmel Mountain Road,
Suite 300, San Diego, CA 92130



(858) 215 -1136

Benefunder is registered as a 501(c)(3) non-profit organization. Contributions to Benefunder are tax-deductible to the extent permitted by law. Benefunder's tax identification number is 46-4303216. The information contained in this material does not constitute legal advice or tax advice. Please consult your CPA or tax professional for advice.